Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyGastroenterologic OncologyGynecological OncologyHead and Neck OncologyThoracic TumorsTumor, regardless of entityDiseaseBile Duct CarcinomaBreast CancerLung Carcinoma, Non-Small CellPancreatic CancerThyroid CancerTumor Biomarker DefinedSubgroupHER2+NRG1-FusionRET fusion positiveICD10C24.-C24.0C24.1C24.8C24.9C25.-C34.-C50.-C73MeSHBile Duct NeoplasmsBiliary TractBiliary Tract NeoplasmsBreast NeoplasmsCarcinoma, Non-Small-Cell LungCommon Bile Duct NeoplasmsPancreatic NeoplasmsThyroid NeoplasmsSequenceChemotherapyChemo-substanceSelpercatinibTrastuzumab emtansineZenocutuzumab Chemo-substanceSelpercatinibTrastuzumab emtansineZenocutuzumab Chemo-substanceSelpercatinibTrastuzumab emtansineZenocutuzumab Chemo-substanceSelpercatinibTrastuzumab emtansineZenocutuzumab No. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronParacetamolSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronParacetamolSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronParacetamolSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronParacetamolNo. Substances24Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationSecond lineseveral possibleTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlAstheniaCardiotoxicityConstipationDiarrheaEmetogenicityEmetogenicity (MASCC/ESMO)HeadacheHepatotoxicityHypertensionIncrease AminotransferasesInfusion ReactionNauseaNeuropathyNeutropeniaPyrexiaQTc Time ExtensionRashThrombocytopenia below 50 000/µlVomiting only studiesPublicationAuthorDrilon AJhaveri KLSchram AMDiseaseRET-bedingte Tumoren, Zweitlinie oder höher, ECOG 0-2Solide Tumoren HER2 amplifiziert, außer Mamma-Ca oder AEG-Tumoren und Magen-Ca, ECOG 0-1Tumore unterschiedlicher Lokalisation, lokal fortgeschritten oder metastasiert, NRG1-Fusion, Zweitlinie, ECOG 0-2OriginMemorial Sloan-Kettering Center, New York, USA, NCI-MATCH trial (EAY131)Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, LIBRETTO-001Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA, eNRGy trialProtocols in Revision 3 protocols foundSelpercatinib 160, Tumor Biomarker Defined (PID1732 V1.0)Trastuzumab Emtansine 3.6, Tumor Biomarker Defined (PID1677 V1.0)Zenocutuzumab 750, Tumor Biomarker Defined (PID3015 V1.0)
